This amount represents the tax effect of gross carryforward losses and deductions with the following expirations: 2021-2022-$79 million 2023-2029-$663 million 2030 and thereafter-$171 million. The amounts are shown after reduction for unrecognized tax benefits of $ 63 million and $115 million as of Decemand 2019, respectively. The decrease in deferred tax liability is mainly due to impairment and amortization. In 20, income before income taxes includes goodwill impairment in non-Israeli subsidiaries that did not have a corresponding tax effect. In 2018, Other, net comprised mainly of a make-whole payment of $46 million following early redemption of senior notes during 2018.
In 2020, Income from investments comprised mainly of revaluation gain of Teva’s investment in American Well Corporation (“American Well”). Including impairments related to exit and disposal activities Includes adjustments for foreign currency translation. Including $514 million convertible notes. Mainly related to the divestment of several activities in our International Markets segment. In March 2020, Teva repaid at maturity $700 million of its 2.25% senior notes. In July 2020, Teva repaid at maturity €1,010 million of its 0.375% senior notes. Contingent consideration represents liabilities recorded at fair value in connection with acquisitions. Accumulated goodwill impairment as of December 31, 2020, Decemand Decemwas approximately $25.6 billion, $21.0 billion and $21.0 billion, respectively. Due to management’s intention and ability to sell this security in the next twelve months, the balance as of Decemwas reclassified to short term investments. By December 31, 2020, Teva recorded an additional gain of $80 million under financial expenses, net, reflecting the revaluation gain of this security as of Decemand transferred it to Level 2 measurement within fair value hierarchy due to a change in discount rate. This represented a transfer into Level 3 measurement within fair value hierarchy.
The investment was reclassified from “investment in associated companies” to “investment in marketable securities,” since Teva no longer had significant influence in American Well. During the third quarter of 2020, Teva recorded a gain of $134 million under share in profits of associated companies, net, reflecting the difference between the book value of Teva’s investment in American Well and its fair value as of the date it completed its initial public offering in September 2020. Following the adoption of ASU 2016-01, the Company recorded a $ 5 million opening balance reclassification from accumulated other comprehensive income to retained earnings. False 2008 2009 2010 2011 P30D FY 0000818686 00-0000000 IL us-gaap:OperatingLeaseLiabilit圜urrent us-gaap:OperatingLeaseLiabilit圜urrent Represents an amount less than 0.5 million.
0 kommentar(er)
